STL Index for: Erythema

Imiquimod 5% cream (Aldara™, Graceway Pharmaceuticals) is an immune response modifier used for the topical treatment of anogenital warts in non-HIV-infected patients. Several randomized controlled trials have demonstrated that imiquimod 5% cream is a safe and efficacious treatment.

Many options exist for the treatment of rosacea, including topical and systemic therapies, laser and light-based therapies, and surgical procedures. The goals of therapy include reduction of papules, pustules, erythema, physical discomfort, and an improvement in quality of life.

Psoriasis is a common chronic inflammatory skin disease that is mediated, in part by the body’s T-cell inflammatory response mechanisms. Current data regarding the efficacy of these agents show they may have the potential to become the new clinical gold standard for biologic therapy to treat psoriasis.

The formation of free radicals is a widely accepted pivotal mechanism leading to skin aging. Topical antioxidants are available in multivariate combinations through over-the-counter skin care products that are aimed at preventing the clinical signs of photoaging.

A vast spectrum of topical anti-acne agents has emerged in response to new insights that have been gained through the understanding of disease pathophysiology and the need for clinicians to adopt an individualized therapeutic approach.

Early diagnosis of psoriatic arthritis (PsA) is essential for preventing disease progression and joint destruction. We will review the presentation and temporal relationship of psoriasis and PsA, the diagnosis, classification, and management and the role of the dermatologist.

Acne vulgaris can represent a therapeutic challenge in terms of managing ongoing symptoms and preventing scar formation. Dermatologists may now have viable new alternatives for treating all grades of acne severity that circumvent the negative side-effects associated with many conventional options.

The epidermal growth factor receptor (EGFR) is often overexpressed or dysregulated in solid tumors. Targeting the EGFR-mediated signaling pathway has become routine practice in the treatment of lung, pancreatic, head and neck, and colon carcinomas.

Side effects, safety and risks of Minocycline (Minocin, Dynacin, Vectrin) are discussed in this article. Topics include drug interactions, bacterial resistance, as well as other adverse effects.

Rosacea is a common condition that affects people of all races. More aggressive and innovative uses of existing oral agents have resulted in novel therapeutic approaches, which can provide long-term therapy and sustained remission.

Intravenous immunoglobulin (IVIG) has been proposed as a treatment for toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS). A multi-center, comparative, long-term analysis needs to be conducted to determine the role of IVIG in the management of patients with SJS/TEN.

Hyperpigmentation disorders of the skin are common and can be the source of significant psychosocial distress for patients. Topical applications are the mainstay of treatment and include phenols, retinoids, corticosteroids, and their combinations.

Novel uses of old medications and new formulations of systemic medications have broadened the therapeutic armamentarium for treating rosacea patients. It is of primary importance to offer patients safe and effective therapies for this chronic and incurable condition, improving both the clinical and psychosocial consequences of rosacea.

Plasma skin regeneration technology uses energy delivered from plasma rather than light or radiofrequency. Plasma skin regeneration technology can be used at varying energies for different depths of effect, from superficial epidermal sloughing to deeper dermal heating.

Common diaper dermatitis is an irritant contact diaper dermatitis (IDD) created by the combined influence of moisture, warmth, urine, feces, friction, and secondary infection. This article will focus on practical management strategies for IDD.

Today, diagnosing and treating rosacea remains a challenge. More studies are necessary to provide additional insight on drugs currently available as well as possible future agents. The ultimate goal is to provide each patient with a treatment regimen best suited for his or her individual needs.

Topical metronidazole has been used for the treatment of rosacea for over 30 years. Several placebo-controlled trials have demonstrated its effectiveness in the treatment of moderate-to-severe rosacea.

There are currently no laboratory tests to diagnose rosacea; it remains a clinical diagnosis. The actual pathophysiology and etiology of rosacea also remain unclear; however, quite recently the spectrum of rosacea has been classified and standardized.

Etanercept has recently been approved for the treatment of moderate-to-severe plaque psoriasis at a dose of 50mg twice per week for 12 weeks followed by a maintenance dose of 50mg once weekly thereafter. Clinical studies have shown excellent efficacy and a good safety profile in patients with psoriasis.

Actinic keratoses (AKs) are premalignant inflammatory skin lesions with the potential to transform into squamous cell carcinoma (SCC). There are several treatment options available for patients presenting with multiple AKs. Imiquimod is believed to stimulate and enhance host immune responses locally against skin tumors and viral infections.

Photodynamic therapy has been used for several years for the treatment of actinic keratoses and prevention of invasive nonmelanoma cancers. Recently, increasing physician expertise with the topical sensitizers and light sources employed in PDT has led to expanded applications.

Wound care after laser skin resurfacing is critical for achieving a successful result. The superficial thermal injury created by laser skin resurfacing heals more quickly and with a reduced risk of scarring under occlusion. Effective management techniques can help minimize expected negative effects.

Seborrheic dermatitis is a common inflammatory skin disease, affecting between 1% and 3% of immunocompetent adults. While its cause is unknown, a number of predisposing factors have been reported, including the implications of Malassezia yeasts.

With so many new peel preparations on the market today, the dermatologist must ask himself basic questions concerning the products. The most important question is directed to the medical literature rather than the advertising or marketing campaign so common among marketdriven cosmetic products.

The exact mechanism of action of leukotriene receptor antagonists in Atopic Dermatitis is not known. In small clinical and case studies, montelukast was found to be a safe and effective alternative or steroid-sparing therapy in the management of patients with atopic dermatitis.

Over the past decade, refinements in laser technology as well as advances in laser techniques have enabled dermatologic surgeons to define the most appropriate lasers to use for different scar types without the adverse sequelae and recurrence rates noted with older surgical revision techniques and continuous wave laser systems.

Nonablative laser and light therapy is a relatively novel modality for the improvement of the visual appearance of photodamaged, scarred, and injured skin. A number of different wavelengths and devices have been purported to be efficacious for the delivery of nonablative therapy.

Imiquimod is the first of a new class of drugs to emerge in the treatment of various dermatologic disorders. As an immune response modifier, it has been shown to have potent antiviral and antitumor properties through the stimulation of innate and cell mediated immune pathways.

Butenafine may be effective and safe in the treatment of interdigital tinea pedis (apply twice daily for 1 week or once daily for 4 weeks), tinea corporis/ tinea cruris (apply twice daily for 2 weeks), and pityriasis versicolor (apply once daily for two weeks).

Acne is a multifactorial disease of the pilosebaceous unit in the skin. Four contributing pathogenic factors need to be elucidated and include excess sebum production, follicular hyperkeratinization, colonization of the pilosebaceous unit by Propionibacterium acnes.

Psoriasis, acne vulgaris and photoaging are common conditions. Tazarotene is a pro-drug of tazarotenic acid, a receptor-selective retinoid, which has shown efficacy in the treatment of these disorders. In the treatment of acne vulgaris, it has greater comedolytic activity than the currently available topical retinoids.

Rosacea is relatively common, typically occurring in individuals of Northern European and Celtic origin between 30 and 50 years of age. It is more common in women, but may be more severe in men. Currently there is no cure available for rosacea, but it can be controlled with topical and oral drug therapy.

ROSASOL Cream is a novel topical formulation of 1% metronidazole in a vehicle containing sunscreens (SPF 15). This product has demonstrated efficacy in the treatment of inflammatory lesions, erythema, and telangiectasiae associated with rosacea.

Imiquimod (S-26308, R-837) (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4 amine), an immune response modifier, was approved as a 5% cream (Aldara, 3M Pharmaceuticals) by the US FDA in February 1997, for the treatment of genital and perianal warts.

Behçet’s disease is an inflammatory disorder of unknown cause. There is often involvement of the gastrointestinal system, the central nervous system and large vessels, which can be life-threatening. As well, ocular lesions can cause blindness. Mucocutaneous symptoms are self-limiting but more frequent.

Clinical rosacea is not a single disease but rather a combination of cutaneous stigmata which include flushing, erythema, telangiectasia, facial edema, papules, pustules, ocular lesions, and rhinophyma. A review of rosacea, treatment, and management.

For Erythema Nodosum Leprosum there are no good alternative treatments to thalidomide. ENL is a severe and painful complication for approximately half of all leprosy patients, affecting about two million people worldwide. A review of thalidomide.